Acute-on-Chronic Liver Failure: Recognition and Management in the Critical Care Setting

Dr Neeraj Manikath ,claude.ai

Abstract

Acute-on-chronic liver failure (ACLF) represents a distinct clinical syndrome characterized by acute decompensation of chronic liver disease with multi-organ failure and high short-term mortality. This condition affects approximately 30-40% of patients hospitalized with decompensated cirrhosis and carries a 28-day mortality rate of 15-35% depending on the grade. Early recognition and prompt management are crucial for improving outcomes. This review provides critical care physicians with evidence-based strategies for diagnosis, risk stratification, and management of ACLF, along with practical pearls and clinical insights derived from recent literature and expert consensus.

Keywords: Acute-on-chronic liver failure, cirrhosis, multi-organ failure, liver transplantation, critical care

Introduction

Acute-on-chronic liver failure (ACLF) has emerged as a critical syndrome distinct from both acute liver failure and stable chronic liver disease. First formally defined by the European Association for the Study of the Liver Chronic Liver Failure (EASL-CLIF) consortium in 2013, ACLF represents a unique pathophysiological entity characterized by acute deterioration of liver function in patients with pre-existing chronic liver disease, often precipitated by identifiable triggers and associated with multi-organ dysfunction.

The syndrome affects a significant proportion of critically ill patients with liver disease, with studies showing that 22-57% of patients with decompensated cirrhosis develop ACLF during hospitalization. The condition is associated with profound inflammatory responses, immune dysfunction, and high short-term mortality rates, making early recognition and appropriate management essential for critical care physicians.

Definition and Diagnostic Criteria

EASL-CLIF Definition

The most widely accepted definition of ACLF comes from the EASL-CLIF consortium, which defines it as a syndrome developing in patients with chronic liver disease with or without previously diagnosed cirrhosis, characterized by acute hepatic decompensation resulting in liver failure and one or more extrahepatic organ failures associated with high short-term mortality.

Asian Pacific Association for the Study of the Liver (APASL) Criteria

The APASL defines ACLF as an acute hepatic insult manifesting as jaundice (serum bilirubin ≥5 mg/dL) and coagulopathy (INR ≥1.5 or prothrombin activity <40%) complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease.

Clinical Pearl: The key distinguishing feature of ACLF is the presence of extrahepatic organ failures, which separates it from simple acute decompensation of cirrhosis.

Pathophysiology

ACLF pathophysiology involves a complex interplay of precipitating factors, systemic inflammation, and multi-organ dysfunction. The syndrome typically follows a "two-hit" model:

First Hit: Chronic Liver Disease

Underlying chronic liver disease creates a state of chronic low-grade inflammation, hepatocyte dysfunction, and architectural distortion. This baseline condition predisposes patients to acute decompensation when exposed to additional stressors.

Second Hit: Precipitating Factors

Acute insults trigger an exaggerated inflammatory response in the setting of chronic liver disease. Common precipitating factors include:

Infections (40-50% of cases): Bacterial infections, particularly spontaneous bacterial peritonitis, pneumonia, and urinary tract infections
Alcohol-related hepatitis: Acute alcoholic hepatitis in chronic alcohol use disorder
Viral hepatitis: Hepatitis B reactivation, hepatitis A or E superinfection
Drug-induced liver injury: Acetaminophen toxicity, herbal medications, antibiotics
Gastrointestinal bleeding: Variceal or non-variceal upper GI bleeding
Surgical procedures: Major surgery or invasive procedures

Clinical Hack: Always search for precipitating factors in ACLF patients, as treating the underlying trigger significantly improves outcomes.

Clinical Recognition and Scoring Systems

CLIF-SOFA Score

The CLIF-SOFA (Sequential Organ Failure Assessment) score is a modified version of the traditional SOFA score, adapted for patients with chronic liver disease. It assesses six organ systems:

Liver: Bilirubin levels
Kidney: Creatinine levels
Brain: Hepatic encephalopathy grade
Coagulation: INR
Circulation: Mean arterial pressure
Lungs: PaO2/FiO2 ratio

ACLF Grading System

Based on the CLIF-SOFA score, ACLF is classified into three grades:

ACLF Grade 1: Single kidney failure or single non-kidney organ failure with kidney dysfunction and/or hepatic encephalopathy grades I-II
ACLF Grade 2: Two organ failures
ACLF Grade 3: Three or more organ failures

Clinical Pearl: The CLIF-SOFA score at admission is the strongest predictor of short-term mortality in ACLF patients.

Diagnostic Approach

Initial Assessment

The diagnostic workup for suspected ACLF should be systematic and comprehensive:

Laboratory Investigations

Complete blood count: Assess for cytopenias, signs of infection
Comprehensive metabolic panel: Liver function tests, renal function, electrolytes
Coagulation studies: PT/INR, aPTT
Inflammatory markers: CRP, procalcitonin, lactate
Arterial blood gas: Assess acid-base status, oxygenation
Ammonia level: Correlates with hepatic encephalopathy severity

Microbiological Workup

Blood cultures: At least two sets from different sites
Urine culture and analysis
Ascitic fluid analysis: Cell count, culture, albumin (if ascites present)
Chest X-ray and sputum culture: If respiratory symptoms

Clinical Hack: Obtain ascitic fluid analysis even in patients without obvious ascites - small amounts can be detected by ultrasound and may reveal occult spontaneous bacterial peritonitis.

Imaging Studies

Abdominal ultrasound with Doppler: Assess liver morphology, portal vein patency, ascites
CT chest/abdomen/pelvis: Evaluate for complications, infections, or malignancy
Echocardiography: Assess cardiac function and rule out cirrhotic cardiomyopathy

Oyster: Cirrhotic cardiomyopathy is often overlooked but can significantly impact hemodynamic management in ACLF patients.

Management Strategies

General Principles

The management of ACLF requires a multidisciplinary approach involving hepatologists, intensivists, and transplant surgeons. Key principles include:

Early recognition and risk stratification
Identification and treatment of precipitating factors
Organ support and prevention of complications
Assessment for liver transplantation eligibility

Specific Interventions

Hemodynamic Management

ACLF patients frequently develop circulatory failure characterized by:

Hyperdynamic circulation: High cardiac output, low systemic vascular resistance
Relative hypovolemia: Due to splanchnic vasodilation
Adrenal insufficiency: Relative or absolute

Management approach:

Fluid resuscitation: Cautious fluid administration to avoid fluid overload
Vasopressor support: Norepinephrine is the preferred first-line vasopressor
Albumin administration: 20-40g daily for volume expansion and anti-inflammatory effects

Clinical Pearl: Albumin in ACLF patients provides both oncotic support and anti-inflammatory benefits through its antioxidant properties.

Respiratory Support

Respiratory failure in ACLF may result from:

Hepatopulmonary syndrome: Intrapulmonary shunting
Portopulmonary hypertension: Pulmonary arterial hypertension
Pleural effusions: Hepatic hydrothorax
Acute lung injury: ARDS-like syndrome

Management strategies:

Oxygen therapy: Maintain SpO2 >90%
Mechanical ventilation: Consider early intubation for severe encephalopathy
Prone positioning: May benefit patients with severe ARDS

Renal Support

Acute kidney injury (AKI) occurs in 50-80% of ACLF patients and significantly impacts prognosis:

Classification of AKI in cirrhosis:

Prerenal AKI: Volume depletion, hypotension
Acute tubular necrosis: Nephrotoxic drugs, sepsis
Hepatorenal syndrome (HRS): Functional kidney failure

Management approach:

Volume optimization: Albumin 1g/kg (max 100g) over 2 days
Discontinue nephrotoxic drugs: Diuretics, NSAIDs, aminoglycosides
HRS treatment: Terlipressin plus albumin or norepinephrine plus albumin
Renal replacement therapy: For severe AKI unresponsive to medical therapy

Clinical Hack: In HRS, the combination of terlipressin and albumin achieves HRS reversal in 40-50% of patients when started early.

Hepatic Encephalopathy Management

Hepatic encephalopathy (HE) is present in 60-80% of ACLF patients and requires aggressive management:

Precipitating factors:

Infections
Gastrointestinal bleeding
Constipation
Electrolyte imbalances

Treatment approach:

Lactulose: 30-45 mL every 2 hours until bowel movement, then 15-30 mL BID
Rifaximin: 550 mg BID for recurrent HE
Zinc supplementation: 220 mg BID
Branched-chain amino acids: May be beneficial in selected patients

Clinical Pearl: Target 2-3 soft bowel movements daily with lactulose therapy - this is the most reliable endpoint for adequate dosing.

Infection Management

Infections are the most common precipitating factor for ACLF and require prompt treatment:

Empirical antibiotic therapy:

Spontaneous bacterial peritonitis: Third-generation cephalosporin (ceftriaxone 2g daily)
Pneumonia: Broad-spectrum coverage based on local resistance patterns
Urinary tract infection: Fluoroquinolones or cephalosporins

Antifungal therapy:

Consider in patients with multiple antibiotic courses or prolonged ICU stay
Candida species are common in this population

Liver Transplantation Considerations

Liver transplantation remains the definitive treatment for ACLF, but patient selection is challenging:

Favorable factors:

Age <65 years
ACLF Grade 1-2
Absence of severe comorbidities
Good functional status prior to illness

Unfavorable factors:

ACLF Grade 3 with >3 organ failures
Severe cardiopulmonary disease
Active malignancy
Ongoing substance abuse

Clinical Pearl: Early transplant evaluation is crucial - outcomes are significantly better when transplantation occurs within 28 days of ACLF diagnosis.

Artificial Liver Support Systems

For patients awaiting transplantation or those with potentially reversible ACLF:

Molecular Adsorbent Recirculating System (MARS):

Removes protein-bound toxins
May improve hepatic encephalopathy and hemodynamics
Limited evidence for survival benefit

Prometheus System:

Combines MARS with hemodialysis
Theoretical advantage in removing both protein-bound and water-soluble toxins

Complications and Their Management

Portal Hypertension-Related Complications

Variceal Bleeding

Acute management: Octreotide, band ligation, balloon tamponade if needed
Antibiotic prophylaxis: Reduces mortality and rebleeding
Transjugular intrahepatic portosystemic shunt (TIPS): Consider in refractory cases

Ascites and Spontaneous Bacterial Peritonitis

Paracentesis: Therapeutic for symptomatic relief
Antibiotic prophylaxis: Norfloxacin 400mg daily for high-risk patients
Albumin infusion: With large-volume paracentesis (>5L)

Metabolic Complications

Hypoglycemia: Common due to impaired gluconeogenesis
Electrolyte imbalances: Hyponatremia, hypokalemia, hypomagnesemia
Acid-base disorders: Metabolic alkalosis or acidosis

Clinical Hack: Check glucose levels frequently in ACLF patients - hypoglycemia can masquerade as worsening encephalopathy.

Prognostic Factors and Outcomes

Short-term Mortality Predictors

CLIF-SOFA score: Most important predictor
Number of organ failures: Higher grade correlates with increased mortality
Age: Patients >65 years have worse outcomes
Lactate levels: Elevated lactate indicates tissue hypoperfusion
Bilirubin trajectory: Rising bilirubin suggests ongoing hepatic injury

Long-term Outcomes

Survivors of ACLF have:

Increased risk of recurrent episodes
Accelerated progression to end-stage liver disease
Higher mortality compared to stable cirrhosis
Reduced quality of life

Clinical Pearl: Even patients who recover from ACLF should be closely monitored and considered for liver transplantation evaluation.

Recent Advances and Future Directions

Biomarkers

Procalcitonin: Better predictor of bacterial infection than traditional markers
Neutrophil-to-lymphocyte ratio: Correlates with inflammation and prognosis
Cytokine profiles: May help guide immunomodulatory therapy

Immunomodulatory Therapies

Corticosteroids: Limited benefit except in alcoholic hepatitis
Mesenchymal stem cells: Promising preliminary results
Plasmapheresis: May reduce inflammatory mediators

Artificial Intelligence

Machine learning models: Improving prognostic accuracy
Real-time monitoring: Continuous assessment of organ function
Personalized medicine: Tailored treatment based on individual risk profiles

Practical Clinical Pearls and Hacks

Pearl 1: The "Golden Hour" Concept

Early recognition and intervention within the first 24 hours significantly impact outcomes. Develop a systematic approach to rapid assessment and risk stratification.

Pearl 2: Albumin is More Than Volume Expansion

Albumin provides anti-inflammatory, antioxidant, and immunomodulatory effects beyond oncotic support. Use liberally in ACLF patients.

Pearl 3: Monitor Trends, Not Just Absolute Values

Daily assessment of organ function trends is more valuable than single time-point measurements. Worsening CLIF-SOFA score predicts poor outcomes.

Hack 1: The "Infection First" Rule

Always assume infection is present until proven otherwise. Start broad-spectrum antibiotics early and narrow based on culture results.

Hack 2: Gentle Fluid Management

Avoid aggressive fluid resuscitation - these patients are intravascularly depleted but total body fluid overloaded. Use albumin for volume expansion.

Hack 3: Early Transplant Discussion

Involve transplant surgery early in the course, even for patients who may not initially meet criteria. Clinical deterioration can be rapid.

Oyster 1: Adrenal Insufficiency

Relative adrenal insufficiency is common in ACLF. Consider hydrocortisone 200-300mg daily in patients with refractory shock.

Oyster 2: Cardiac Complications

Cirrhotic cardiomyopathy manifests as impaired stress response rather than resting dysfunction. Monitor closely during fluid shifts and procedures.

Oyster 3: Coagulation Paradox

Despite elevated INR, ACLF patients may have increased thrombotic risk due to reduced natural anticoagulants. Balance bleeding and thrombosis prophylaxis carefully.

Quality Improvement Initiatives

Standardized Protocols

ACLF recognition bundles: Systematic screening tools
Treatment algorithms: Evidence-based management pathways
Multidisciplinary rounds: Daily involvement of hepatology, critical care, and transplant teams

Outcome Metrics

Time to antibiotic administration: For suspected infections
Transplant evaluation timeframes: Early assessment protocols
Complication rates: Standardized monitoring and reporting

Conclusion

Acute-on-chronic liver failure represents a complex syndrome requiring specialized knowledge and multidisciplinary care. Early recognition, prompt treatment of precipitating factors, appropriate organ support, and timely transplant evaluation are essential for optimal outcomes. Critical care physicians must be familiar with the unique pathophysiology and management principles of ACLF to provide effective care for these challenging patients.

The field continues to evolve with new biomarkers, therapeutic targets, and artificial intelligence applications. However, the fundamental principles of early recognition, systematic assessment, and aggressive supportive care remain the cornerstones of successful management.

As our understanding of ACLF pathophysiology deepens, the potential for targeted therapies and improved outcomes continues to grow. Critical care physicians play a crucial role in this journey, providing the specialized intensive care required while facilitating the multidisciplinary approach essential for optimal patient outcomes.

References

Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437.
Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353-390.
Arroyo V, Moreau R, Jalan R, Ginès P. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. J Hepatol. 2015;62(1 Suppl):S131-143.
Fernández J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67(10):1870-1880.
Gustot T, Fernandez J, Garcia E, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62(1):243-252.
Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut. 2017;66(3):541-553.
Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038-1047.
Karvellas CJ, Francescutti V, Brindle M, et al. Practical management of acute-on-chronic liver failure in the intensive care unit. World J Hepatol. 2018;10(9):608-618.
Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Incidence and Mortality of Acute-on-Chronic Liver Failure Using a United States National Database. Am J Gastroenterol. 2019;114(8):1326-1335.
Mezzano G, Juanola A, Cardenas A, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut. 2022;71(1):148-155.
Saliba F, Camus C, Durand F, et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med. 2013;159(8):522-531.
Sundaram V, Jalan R, Wu T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation. Gastroenterology. 2019;156(5):1381-1391.
Trebicka J, Fernandez J, Papp M, et al. PREDICT study: The clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. J Hepatol. 2020;73(4):793-804.
Wong F, Piano S, Singh V, et al. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. J Hepatol. 2021;74(2):330-339.
Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2018;67(12):2181-2191.

Conflict of Interest Statement: The authors declare no conflicts of interest.

Funding: This work received no specific funding.

Saturday, July 12, 2025